Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

41 42 Next >

Why NYSE:NVS is a Top Pick for Dividend Investors. ↗

October 09, 2024

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

Via Chartmill

Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear ↗

October 03, 2024

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Via Investor's Business Daily

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗

October 01, 2024

HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...

Via Benzinga

Topics Economy

The Importance of Managing Bad Cholesterol: What You Should Know

September 27, 2024

(BPT) - Sponsored by Novartis Pharmaceuticals Corporation

Via Brandpoint

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗

September 13, 2024

Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals.

Via Chartmill

NYSE:NVS: good value for what you're paying. ↗

September 03, 2024

Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Uncovering Dividend Opportunities with NYSE:NVS. ↗

August 23, 2024

Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗

September 18, 2024

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...

Via Benzinga

Topics Intellectual Property

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗

September 18, 2024

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...

Via Benzinga

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 11, 2024

Via Benzinga

Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR. ↗

August 07, 2024

The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout?

Via Chartmill

Why NYSE:NVS is a Top Pick for Dividend Investors. ↗

August 02, 2024

Why the dividend investor may take a look at NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts ↗

September 05, 2024

Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.

Via Benzinga

S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 05, 2024

Via Benzinga

Topics Stocks

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study ↗

August 28, 2024

Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in...

Via Benzinga

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗

August 26, 2024

The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.

Via Investor's Business Daily

Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal ↗

August 26, 2024

Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemicals used in PET scans to enhance its European presence and cancer imaging...

Via Benzinga

2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200 ↗

August 18, 2024

These companies' growth paths should only be briefly interrupted by headwinds.

Via The Motley Fool

Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug ↗

August 13, 2024

Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore...

Via Benzinga

FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease ↗

August 08, 2024

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression....

Via Benzinga

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗

August 06, 2024

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Via Benzinga

Topics Lawsuit

AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗

July 23, 2024

The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.

Via Benzinga

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Novartis Ag (NVS) Q2 2024 Earnings Call Transcript ↗

July 18, 2024

NVS earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Why Novartis Stock Is Down Today Despite Topping Q2 Estimates ↗

July 18, 2024

Investors were caught off guard by a decision on the research and development front.

Via The Motley Fool

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today